Dr. Rocher is a medicinal chemistry and drug discovery expert with more than 25 years industry experience. Joining Addex at its inception in 2002, Dr. Rocher established the company's chemistry capabilities and built Addex' small molecule allosteric modulator chemistry platform. He played a pivotal role in the success of both internal and partnered programs, including the discovery of dipraglurant and ADX71149, both of which progressed into phase II clinical development. Dr. Rocher now returns to Addex from his current position as CNS Program Director at Pierre Fabre.

"I'm delighted to rejoin Addex and have the opportunity to continue the work that Robert Lütjens and I started in 2002", commented Jean-Philippe Rocher. "Allosteric modulation is an exciting field which holds huge potential to transform the treatment of CNS disorders. I am looking forward to deploying my expertise and experience back at Addex."

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs.